You are here

schizophrenia

Roche Terminates Second Phase II Schizophrenia Trial

Roche Terminates Second Phase II Schizophrenia Trial

BioSpace

clinical trials

Flag link:

J&J beats back Viatris' generic challenge to schizophrenia med Invega Trinza

J&J beats back Viatris' generic challenge to schizophrenia med Invega Trinza

Fierce Pharma

Flag link:

Teva, MedinCell win FDA approval for slow-release schizophrenia drug Uzedy

Teva, MedinCell win FDA approval for slow-release schizophrenia drug Uzedy

Fierce Pharma

Teva Pharmaceutical

Flag link:

Schizophrenia: Four major clinical trials to watch in 2023

Schizophrenia: Four major clinical trials to watch in 2023

Clinical Trials Arena

clinical trials

Flag link:

Royalty Pharma hands off $100M upfront for PureTech royalty on Karuna's schizophrenia hopeful

Royalty Pharma hands off $100M upfront for PureTech royalty on Karuna's schizophrenia hopeful

Endpoints

Karuna Therapeutics

Flag link:

Karuna’s schizophrenia drug succeeds in a second late-stage trial

Karuna’s schizophrenia drug succeeds in a second late-stage trial

BioPharma Dive

clinical trials

Flag link:

Newron’s Schizophrenia Candidate Gets Better Over Time

Newron’s Schizophrenia Candidate Gets Better Over Time

BioSpace

Flag link:

Following in Lilly's footsteps, Teva takes 2nd long-acting schizophrenia drug into phase 3

Following in Lilly's footsteps, Teva takes 2nd long-acting schizophrenia drug into phase 3

Fierce Pharma

Teva Pharmaceutical

clinical trials

Flag link:

Luye claims its first FDA approval, for bi-weekly schizophrenia drug

Luye claims its first FDA approval, for bi-weekly schizophrenia drug

Pharmaphorum

Flag link:

JPM23: Karuna CEO says biotech can launch drugs, too, as deal rumors circulate

JPM23: Karuna CEO says biotech can launch drugs, too, as deal rumors circulate

Fierce Biotech

Karuna Therapeutics

Flag link:

Karuna parts ways with executive as it gears up for schizophrenia drug's high-profile launch

Karuna parts ways with executive as it gears up for schizophrenia drug's high-profile launch

Fierce Biotech

Karuna Therapeutics

Flag link:

Newron says pivotal treatment-resistant schizophrenia trial is a go

Newron says pivotal treatment-resistant schizophrenia trial is a go

Pharmaphorum

clinical trials

Flag link:

Boehringer Ingelheim deepens its collaboration with Click Therapeutics in a deal worth $460M

Boehringer Ingelheim deepens its collaboration with Click Therapeutics in a deal worth $460M

Endpoints

Boehringer Ingelheim

Click Therapeutics

digital therapeutics

Flag link:

Karuna switches CEOs ahead of FDA filing for schizophrenia drug

Karuna switches CEOs ahead of FDA filing for schizophrenia drug

BioPharma Dive

Karuna Therapeutics

Flag link:

Take 2: Teva refiles for approval of long-acting schizophrenia drug months after FDA rejection

Take 2: Teva refiles for approval of long-acting schizophrenia drug months after FDA rejection

Fierce Pharma

Teva Pharmaceutical

Flag link:

Neurocrine randomizes first patient in Phase II schizophrenia therapy trial

Neurocrine randomizes first patient in Phase II schizophrenia therapy trial

Clinical Trials Arena

Neurocrine Biosciences

clinical trials

Flag link:

Minerva Shares Plunge After FDA Rejects Schizophrenia Drug Candidate

Minerva Shares Plunge After FDA Rejects Schizophrenia Drug Candidate

BioSpace

Minerva Neurosciences

Flag link:

Royalty Pharma bets Merck's schizophrenia drug can go where Pfizer, Takeda and Lundbeck's couldn’t

Royalty Pharma bets Merck's schizophrenia drug can go where Pfizer, Takeda and Lundbeck's couldn’t

Endpoints

Flag link:

FDA accepts Otsuka, Lundbeck filing for long-acting schizophrenia drug, teeing up April decision date

FDA accepts Otsuka, Lundbeck filing for long-acting schizophrenia drug, teeing up April decision date

Fierce Pharma

bipolar disorder

Abilify Maintena

Flag link:

Maplight concludes Phase I trial of schizophrenia and dyskinesia therapy

Maplight concludes Phase I trial of schizophrenia and dyskinesia therapy

Clinical Trials Arena

Maplight Therapeutics

clinical trials

Flag link:

Pages